Newron Pharmaceuticals (OTCMKTS:NWPHF) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Newron Pharmaceuticals (OTCMKTS:NWPHF) from a buy rating to a hold rating in a research report sent to investors on Thursday morning, Zacks.com reports.

According to Zacks, “Newron Pharmaceuticals SpA is a biopharmaceutical company. It focuses on the discovery and development of drugs for the treatment of central nervous system disorders and pain primarily in Italy and internationally. Newron Pharmaceuticals SpA is headquartered in Bresso, Italy. “

Shares of NWPHF opened at $9.25 on Thursday. The company’s 50-day moving average is $9.25. Newron Pharmaceuticals has a 1-year low of $7.98 and a 1-year high of $9.25.

Newron Pharmaceuticals Company Profile

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease.

Read More: Why does a company issue an IPO?

Get a free copy of the Zacks research report on Newron Pharmaceuticals (NWPHF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Newron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.